Overall, event-free, relapse-free survival improved in patients receiving higher doses of tisagenlecleucel, with no increased toxicity<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Aug. 9, 2022 (HealthDay News) — For pediatric patients with B-cell acute lymphoblastic leukemia, higher doses of tisagenlecleucel, the chimeric antigen receptor T (CAR T)-cell therapy targeting CD19, are associated with improved survival, according to a study published online Aug. 8 in Blood Advances<\/em>.\n<\/p>\n \n\tHeather E. Stefanski, M.D., Ph.D., from the National Marrow Donor Program and the University of Minnesota Medical School in Minneapolis, and colleagues examined whether CAR T-cell dose impacts overall survival, event-free survival, and relapse-free survival in recipients of tisagenlecleucel using data from 185 pediatric patients infused with commercial tisagenlecleucel. To examine the impact of cell dose, responders were categorized into dose quartiles.\n<\/p>\n \n\tThe researchers found that patients who received higher doses of tisagenlecleucel had improved overall survival, event-free survival, and relapse-free survival. There was no association observed for higher doses of tisagenlecleucel with increased toxicity.\n<\/p>\n \n\t“In the past, we did not have data to guide clinical decisions around commercial CAR T-cell dosing and didn’t know if higher doses would affect toxicity and compromise outcomes, or support enhanced antileukemia effect,” a coauthor said in a statement. “This data has direct clinical applicability, as it supports use of higher dosing, as available, within the approved tisagenlecleucel dose range.”\n<\/p>\n \n\tSeveral authors disclosed financial ties to pharmaceutical companies, including Novartis, the manufacturer of tisagenlecleucel.\n<\/p>\n